Becton Dickinson and Co (BDX) : Bryn Mawr Trust Co scooped up 22,948 additional shares in Becton Dickinson and Co during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 3, 2016. The investment management firm now holds a total of 146,219 shares of Becton Dickinson and Co which is valued at $24,102,740.Becton Dickinson and Co makes up approximately 1.55% of Bryn Mawr Trust Co’s portfolio.
Other Hedge Funds, Including , Geneva Advisors reduced its stake in BDX by selling 3,536 shares or 0.82% in the most recent quarter. The Hedge Fund company now holds 429,317 shares of BDX which is valued at $70,768,614. Becton Dickinson and Co makes up approx 1.42% of Geneva Advisors’s portfolio.American Research Management reduced its stake in BDX by selling 1,055 shares or 82.36% in the most recent quarter. The Hedge Fund company now holds 226 shares of BDX which is valued at $36,445. Becton Dickinson and Co makes up approx 0.02% of American Research Management’s portfolio.Hhg Company reduced its stake in BDX by selling 271 shares or 1.43% in the most recent quarter. The Hedge Fund company now holds 18,706 shares of BDX which is valued at $2,990,715. Becton Dickinson and Co makes up approx 0.82% of Hhg Company’s portfolio.Aull Monroe Investment Management Corp boosted its stake in BDX in the latest quarter, The investment management firm added 200 additional shares and now holds a total of 1,600 shares of Becton Dickinson and Co which is valued at $255,808. Becton Dickinson and Co makes up approx 0.15% of Aull Monroe Investment Management Corp’s portfolio.Private Trust Co Na reduced its stake in BDX by selling 24 shares or 1.46% in the most recent quarter. The Hedge Fund company now holds 1,622 shares of BDX which is valued at $259,325. Becton Dickinson and Co makes up approx 0.07% of Private Trust Co Na’s portfolio.
Becton Dickinson and Co opened for trading at $165.85 and hit $168.32 on the upside on Tuesday, eventually ending the session at $167.64, with a gain of 1.00% or 1.66 points. The heightened volatility saw the trading volume jump to 12,28,904 shares. Company has a market cap of $35,574 M.
On the company’s financial health, Becton Dickinson and Co reported $2.18 EPS for the quarter, beating the analyst consensus estimate by $ 0.17 according to the earnings call on May 5, 2016. Analyst had a consensus of $2.01. The company had revenue of $3067.00 million for the quarter, compared to analysts expectations of $3073.41 million. The company’s revenue was up 49.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.61 EPS.
Many Wall Street Analysts have commented on Becton Dickinson and Co. Company shares were Reiterated by RBC Capital Mkts on May 9, 2016 to “Sector Perform”, Firm has raised the Price Target to $ 169 from a previous price target of $153 .Company shares were Upgraded by Deutsche Bank on Feb 11, 2016 to ” Buy”, Firm has raised the Price Target to $ 163 from a previous price target of $155 .Shares were Reiterated by RBC Capital Mkts on Feb 4, 2016 to “Sector Perform” and Lowered the Price Target to $ 153 from a previous price target of $162 .
Becton Dickinson and Company is a global medical technology company engaged in the development manufacture and sale of a range of medical supplies devices laboratory equipment and diagnostic products used by healthcare institutions life science researchers clinical laboratories pharmaceutical industry and the general public. The Company operates through two segments: BD Medical and BD Life Sciences. The Company’s Life Sciences segment consists of the BD Diagnostics and BD Biosciences segments. The Company’s BD Medical segment focuses on providing solutions to reduce the spread of infection enhance diabetes treatment and advance drug delivery. The Company’s BD Diagnostics provides products for the safe collection and transport of diagnostics specimens as well as instruments and reagent systems. Its BD Biosciences provide diagnostic and research tools to life science researchers clinical researchers laboratory professionals and clinicians.